尿激酶与血管舒缓素联用治疗急性脑梗塞疗效观察  

Clinical Study of the Associated Use of Urokinase and Kallikrein for the Treatment of Acute Cerebral Infarction

作　　者：李忠山[1] 郭西文[1] 陈宝琅[1] 季秀丽[2] 晁金梅 

机构地区：[1]菏泽医学专科学校,山东菏泽274030 [2]菏泽市立医院,山东菏泽274031 [3]菏泽市第二人民医院,山东菏泽274036

出　　处：《中国误诊学杂志》2003年第12期1798-1799,共2页Chinese Journal of Misdiagnostics

摘　　要：目的 :探讨尿激酶与血管舒缓素联用治疗急性脑梗塞的方法及效果。方法 :86例急性脑梗塞患者被随机分成治疗组与对照组 ,对照组进行常规治疗 ,而治疗组在常规治疗基础上加用尿激酶与血管舒缓素进行溶栓治疗 ;然后进行疗效观察 ,所获数据进行χ2 或 t检验。结果 :治疗后治疗组神经功能缺损评分显著低于对照组 (P<0 .0 1) ,治愈率及总有效率均显著高于对照组 (P<0 .0 5 ) ,血流动力学改善显著优于对照组 (P<0 .0 5 ) ;且治疗期间未发生严重并发症。结论 :尿激酶与血管舒缓素联用治疗急性脑梗塞是一种安全、有效的治疗方法。Objective:To investigate the efficacy of urokinase combined with kallikrein in the treatment of acute cerebral infarction (ACI).Methods:86 ACI patients were divided into therapeutic group and control group randomly, patients in control group were treated by routine therapy ,and the patients in therapeutic group received thrombolytic therapy (urokinase and kallikrein) besides routine treatment;then observe their therapeutic efficacy. The datas were tested by χ2 or t test.Results:After therapy,the therapy group′s neurologic deficit scale were lower than control group′s significantly(P<0.01), cure rate and total effective rate were higher than control group′s significantly(P<0.05), improvement of hemorrhelogy were superior to control group(P<0.05) ,and without main complications.Conclusions:Urokinase combined with kallikrein for treated ACI was safe and effective.

关 键 词：尿纤溶酶原激活物/治疗应用 激肽释放酶类/治疗应用 脑梗塞/药物疗法 药物疗法 联合 

分 类 号：R743.33[医药卫生—神经病学与精神病学]